Titration of amlodipine to higher doses: a comparison of Asian and Western experience

Kazuomi Kario1
Jeffery Robbins2
Barrett W Jeffers2
1Division of Cardiovascular Medicine, Jichi Medical University, Shimotsuke, Japan; 2Pfizer, New York, NY, USA

Abstract: In this retrospective analysis, data pooled from two Phase III/IV open-label Asian studies were used to quantify the additional blood pressure efficacy achieved when titrating amlodipine from 5 mg to 10 mg in mild/moderate hypertensive patients, and compared to data pooled from three Western studies. The primary efficacy end point was the change from baseline in sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) to the specified time point (4–8 weeks, depending on the trial). For the Asian analysis (n=174), both mean SBP and DBP were significantly decreased at the final visit (SBP −13.3 mmHg, 95% confidence interval [CI] −15.5 to −11.0; DBP −9.2 mmHg, 95% CI −10.6 to −7.8; both P<0.0001). These results were similar to the Western analysis (n=369; SBP −11.5 mmHg, 95% CI −13.1 to −10.0; DBP −6.3, 95% CI −7.1 to −5.5; both P<0.0001). In summary, titration of amlodipine from 5 mg to 10 mg significantly decreased both SBP and DBP in Asian patients with mild-to-moderate hypertension.

Keywords: amlodipine, hypertension, Asia

Introduction

Hypertension increases the risk of vascular disease, including stroke, myocardial infarction, nephropathy, and retinopathy,1–3 and is a highly prevalent and modifiable risk factor for cardiovascular disease in both economically developed and developing countries. Even small changes in blood pressure have been shown to lower the risk of stroke (by 35%–50%), myocardial infarction (by 20%–25%), and heart failure (by >50%).4–7 However, pharmacological intervention is usually required to achieve this.

Calcium-channel blockers (CCBs), including amlodipine, are an effective treatment option for hypertension, as their efficacy is affected neither by age nor ethnicity and because both the risks of cardiovascular events and all-cause mortality are reduced.8 Furthermore, CCBs may have better efficacy for preventing stroke than other classes of antihypertensive agents;7 however, the degree of blood pressure reduction appears to be an important determinant of the size of this treatment effect.8–10 The efficacy of amlodipine for the treatment of hypertension in both normal- and high-cardiovascular-risk hypertensive patients has been demonstrated in multiple large clinical trials,5,11 and CCBs are included in various clinical guidelines as first-line recommendations for hypertension.1,12–14

In the Asia-Pacific region, hypertension may contribute to up to 66% of cardiovascular diseases.15 Research has demonstrated a linear relationship between blood pressure and stroke, and furthermore that the association between blood pressure and stroke
is stronger in Asian than Caucasian patients.\textsuperscript{16,17} Although the efficacy and safety of amlodipine 10 mg has been confirmed in multiple studies,\textsuperscript{18–21} the option of increasing the amlodipine dose from 5 mg to 10 mg in patients who may benefit from the higher dose has been met with reluctance among some practitioners, especially in Japan, possibly due to concern about adverse events (AEs) (eg, pedal edema) with the 10 mg dose.\textsuperscript{22}

The objective of this study was to quantify the additional blood pressure efficacy achieved when titrating hypertensive Asian patients from amlodipine 5 mg to 10 mg and to compare this with data from Western patients.

Materials and methods

Study design

This was a post hoc, retrospective, pooled analysis. Data from two similarly designed Phase III/IV open-label studies (AML-NY-93-002 and A0531086 [Pfizer data on file]) investigating the safety and efficacy of amlodipine in Asian patients with mild or moderate hypertension were pooled and compared with data pooled from three Western studies (A0531004, A0531044, and A053R0510 [Pfizer data on file]). Eligible patients were male and female, age ≥18 years with mild or moderate hypertension (diastolic blood pressure [DBP] ≥95 to ≤120 mmHg, systolic blood pressure [SBP] >140 to <200 mmHg). The five studies included in this analysis enrolled patients that mirrored actual clinical practice. Namely, they were a mixture of treatment-naïve patients and others who were uncontrolled on prior antihypertensives. All patients remained on stable treatment throughout the study.

Patients received amlodipine at a dose of 5 mg daily for 4–8 weeks, and were then allowed to titrate to 10 mg daily as needed, for an additional 4–8 weeks of treatment. Primary efficacy end points were the change from baseline in sitting SBP and sitting DBP. Baseline was established prior to titration, ie, after patients had received amlodipine 5 mg daily for 4–8 weeks. Safety end points included assessment of AEs.

Assessments

Efficacy analyses included all patients in the intent-to-treat population who were titrated from 5 mg to 10 mg and had both a baseline and follow-up blood pressure measurement. Safety was assessed by measurement of the frequency of treatment-emergent serious AEs (all-causality), treatment-emergent serious AEs (all-causality), and AEs resulting in withdrawal from treatment (all-causality). Safety analyses included all patients who were titrated from 5 mg to 10 mg amlodipine.

Statistical analyses

The last observation carried forward was used to impute the end of study blood pressures for those patients who withdrew early. Descriptive statistics were used for quantitative variables and frequency counts by category for qualitative variables. A single-sample $t$-test was used to test the null hypothesis of no mean change from baseline in blood pressure, along with corresponding 95% confidence interval (CI).

Results

Study population

Of the 174 patients included in the Asian analysis, 69 (40%) were from Japan, with the remaining patients distributed across the People’s Republic of China, Hong Kong, Indonesia, South Korea, the Philippines, Taiwan, and Thailand. Just over half of the patients were male, and the mean age of patients was 55.9 years (Table 1). The baseline mean (standard error [SE]) SBP was 149.3 (1.28) mmHg and DBP was 93.0 (0.84) mmHg. For the Western analysis, 206/383 (53.8%) patients were male, the mean age was 59.6 years, and the baseline mean (SE) SBP was 151.4 (0.82) mmHg and DBP was 90.5 (0.48) mmHg (Table 1).

Of the 174 patients included in the Asian analysis, 100% were treated and included in the efficacy and safety analyses. A total of 159 (91.4%) patients completed the study, and 15 (8.6%) discontinued. Reasons for discontinuation included AEs (n=9, 5.2%); withdrawal of consent and other (both n=1, 0.6%). For comparison, in the Western studies, 353 of 385 (91.7%) completed the study, and 32 of 385 (8.3%) discontinued due to AEs (24, 6.2%), patient no longer willing to participate (four, 1.0%), other, and protocol violation (both two, 0.5%).

Efficacy

Titration of amlodipine from 5 mg daily to 10 mg daily resulted in a statistically significant decrease in blood pressure.

Table 1 Baseline characteristics of the pooled Asian and Western populations

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Asian (n=174)</th>
<th>Western (n=385)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, n (%)</td>
<td>96 (55.2)</td>
<td>206 (53.8)</td>
</tr>
<tr>
<td>Age, mean, years (SD)</td>
<td>55.9 (10.82)</td>
<td>59.6 (10.9)</td>
</tr>
<tr>
<td>Weight, kg (SD)</td>
<td>67.0 (12.16)</td>
<td>84.3 (15.7)</td>
</tr>
<tr>
<td>BMI, kg/m(^2) (SD)</td>
<td>25.5 (3.77)</td>
<td>29.3 (4.3)</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; SD, standard deviation.
Amlodipine 10 mg lowered SBP by −13.3 mmHg (95% CI −15.5 to −11.0) and DBP by −9.2 mmHg (95% CI −10.6 to −7.8) at the final visit (P<0.0001 for both) (Figure 1). These results were similar to those of the pooled analysis of three Western studies (SBP −11.5 mmHg, 95% CI −13.1 to −10.0; DBP −6.3 mmHg, 95% CI −7.1 to −5.5; both P<0.0001; Figure 2).

Safety
A total of 65 of 174 (37.4%) Asian patients experienced 142 AEs (Table 2), of which infections 14.9% (26), musculoskeletal 12.6% (22), gastrointestinal 9.8% (17), and general disorders 9.8% (17) were the most commonly reported postbaseline. Peripheral edema occurred in eleven of 174 (6.3%) patients. Serious AEs were reported by four patients (one cardiac disorder, 0.6%; three neoplasms, 1.7%). Treatment was withdrawn from nine patients due to an AE. Of the AEs that led to treatment withdrawal, neoplasms (n=3, 1.7%), general disorders (n=2, 1.1%), and nervous system disorders (n=2, 1.1%) occurred in one or more patients; cardiac disorders, gastrointestinal disorders, infections and investigations, each occurred in one patient. None of the patients discontinued treatment due to peripheral edema.

For comparison, in the Western studies, 100 of 385 (26.0%) patients experienced 174 AEs (Table 2). Peripheral edema occurred in 35 of 385 (9.1%) patients. Serious AEs were reported by two patients (cardiac disorder, n=1, 0.3%; infections and infestations, n=1, 0.3%; and nervous system disorders, n=2, 0.5%). Treatment was withdrawn from 14 patients due to an AE. Of the AEs that led to treatment withdrawal, general disorders (n=10, 2.6%); musculoskeletal and connective tissue disorders (n=3, 0.8%); nervous system disorders (n=3, 0.8%); psychiatric disorders (n=2, 0.5%), respiratory, thoracic, and mediastinal (n=2, 0.5%), skin and subcutaneous tissue (n=2, 0.5%), and vascular disorders (n=2, 0.5%) occurred in two or more patients. Nine (2.3%) patients discontinued treatment due to peripheral edema.

Discussion
Although the need for effective management of blood pressure is well understood, adherence to antihypertensive treatment and blood pressure control continues to be a challenging international health goal. In recent guidelines, eg, those

![Figure 1](image-url)  
**Figure 1** Blood pressure of patients titrated from amlodipine 5 mg to 10 mg from the pooled analysis of Asian studies, at baseline and final visit.  
*Notes:* Analyses conducted using the intent-to-treat population. *P*-values and corresponding confidence intervals (CIs) were computed using a single-sample *t*-test; ^a^baseline established while on amlodipine 5 mg.  
*Abbreviation:* BP, blood pressure.
produced by the European Society of Hypertension/European Society of Cardiology,24 CCBs, such as amlodipine, are recommended as first-line antihypertensive agents.

The efficacy of amlodipine monotherapy in reducing blood pressure is well established in a number of populations, including patients aged ≥65 years,25 pediatric patients,26 patients treated at primary and also specialized care centers,27 and patients of different ethnic origin.28 The results of a meta-analysis suggest that CCBs have better efficacy for preventing stroke than other classes of antihypertensive agents.7 Another meta-analysis determined that this benefit of CCBs extended to reduction in the risk for cardiovascular death, major cardiovascular events, and heart failure.8 For patients who receive amlodipine, the size of the reduction in risk of stroke is largely dependent on the magnitude of the reduction in blood pressure achieved.9 In particular, the association between blood pressure and stroke is known to be stronger in Asian than Caucasian patients.16,17 Furthermore, other research suggests that in addition to its antihypertensive-related effect, amlodipine has a blood pressure-independent beneficial effect on stroke risk;9,10 administration of amlodipine may lead to enhanced endothelial nitric oxide production, inhibition of smooth-muscle cell proliferation, and antioxidant activity: effects not characteristic of some of the other CCBs.29,30 Recent evidence also suggests amlodipine lowers levels of highly sensitive cardiac troponin – which is associated with cardiovascular disease, mortality, and heart failure – to a greater extent than the combination of losartan and hydrochlorothiazide.31

**Table 2** Incidence of adverse events for the pooled Asian and Western populations

<table>
<thead>
<tr>
<th></th>
<th>Asian (n=174)</th>
<th>Western (n=385)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AEs</td>
<td>142</td>
<td>174</td>
</tr>
<tr>
<td>Patients with AEs, n (%)</td>
<td>65 (37.4)</td>
<td>100 (26.0)</td>
</tr>
<tr>
<td>Patients with SAEs, n (%)</td>
<td>4 (2.3)</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>Patients discontinued study due to AEs, n (%)</td>
<td>9 (5.2)</td>
<td>14 (3.6)</td>
</tr>
<tr>
<td>Most common all-cause AEs (≥2% of patients), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>19 (10.9)</td>
<td>5 (1.3)</td>
</tr>
<tr>
<td>Edema, peripheral</td>
<td>11 (6.3)</td>
<td>35 (9.1)</td>
</tr>
<tr>
<td>Back pain</td>
<td>8 (4.6)</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>Diabetes melitus</td>
<td>4 (2.3)</td>
<td>0</td>
</tr>
<tr>
<td>Flushing</td>
<td>4 (2.3)</td>
<td>0</td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>4 (2.3)</td>
<td>2 (0.5)</td>
</tr>
</tbody>
</table>

**Notes:** *Pooled Asian population. All patients were titrated from amlodipine 5 mg to 10 mg postbaseline.

**Abbreviations:** AEs, adverse events; SAEs, serious adverse events.
There is a significant association between disrupted diurnal variations in blood pressure and cardiovascular disease. Nondippers with diminished nocturnal blood pressure fall, and risers with higher nocturnal blood pressure than daytime blood pressure are associated with target-organ damage and subsequent cardiovascular events. In addition, exaggerated morning surge is an independent predictor of cardiovascular events. Amiodipine maintains blood pressure in patients with diurnal variations in blood pressure, eg, it attenuates morning surge in blood pressure in hypertensive individuals. A once-daily dose of long-acting amiodipine can control ambulatory blood pressure throughout a 24-hour period in elderly uncomplicated hypertensive patients with different nighttime blood pressure dipping. The ALPHABET study demonstrated that the effects of high-dose (10 mg) amiodipine on clinic, home, and ambulatory blood pressure control, and brain natriuretic peptide reduction were similar to the combination of losartan and hydrochlorothiazide. Furthermore, amiodipine may have additional protective benefits in not reducing nocturnal blood pressure to the extent that it accelerates brain ischemia in some hypertensive patients with marked nocturnal blood pressure reduction.

In this retrospective post hoc analysis, the titration of amiodipine from 5 mg to 10 mg daily significantly decreased both SBP and DBP in Asian patients with mild-to-moderate hypertension. Amiodipine 10 mg lowered SBP by −13.3 mmHg (95% CI −15.5 to −11.0) and DBP by −9.2 mmHg (95% CI −10.6 to −7.8) at the final visit (P<0.0001 for both). Not only were the results from this analysis similar to those of the pooled analysis of three Western studies, they also provide support for other studies that have also shown the benefits of titrating from amiodipine 5 mg to 10 mg in hypertensive Asian patients. In the Amiodipine Cohort Study by Internet-Based Research for Evaluation of Efficacy (ACHIEVE), Kario et al reported that in poorly controlled hypertensive Japanese patients, titration from amiodipine 5 mg to 10 mg daily significantly reduced both home and clinic blood pressure. Furthermore, these reductions seemed to be more pronounced among patients with higher baseline blood pressure than in those with lower baseline blood pressure values. In another study, Uno et al compared the efficacy and tolerability of amiodipine 5 mg and 10 mg in Japanese hypertensive patients, and found that amiodipine 10 mg resulted in greater reductions in blood pressure versus amiodipine 5 mg. These blood pressure reductions were also shown to be significantly correlated with reductions in both hypertensive cardiac overload and renal damage (measured by brain natriuretic peptide and microalbuminuria levels, respectively). The wealth of studies reporting not only the dangers of sustained hypertension on the risk of cardiovascular events but also the benefits of uptitration to amiodipine 10 mg in reducing elevated blood pressure highlights the importance of encouraging this strategy in prescribing patterns.

Overall, more AEs were reported in the Asian population than in the Western population (37% versus 26%). In particular, AEs of nasopharyngitis, back pain, diabetes mellitus, and flushing were all four times more common in the Asian population versus the Western population. Whereas it is well documented that diabetes is more prevalent in Asian subjects, the reason for the higher incidences of nasopharyngitis, back pain, and flushing reported in Asian subjects in this analysis is unknown. A possible explanation for the higher incidence of nasopharyngitis observed in Asian versus Western patients is that it has been reported that the Asians are more susceptible to catching colds than those from any other region; however, literature to support this theory is currently limited, and further research is required.

It has been reported that some practitioners in Asia, particularly Japan, are reluctant to prescribe a higher dose of amiodipine, perhaps due to concerns about an increased incidence of pedal edema with the 10 mg dose. Of the 174 patients included in this pooled analysis, peripheral edema occurred in eleven patients (6.3%). Furthermore, there were no treatment discontinuations as a result of peripheral edema, demonstrating that despite concerns, the increased dose of amiodipine is not associated with a worsened safety signal.

In summary, in this retrospective post hoc analysis, the titration of amiodipine from 5 mg to 10 mg daily significantly decreased both SBP and DBP in Asian patients with mild-to-moderate hypertension. The findings of this analysis support the uptitration of amiodipine from 5 mg to 10 mg in order to reduce blood pressure in Asian patients with hypertension.

Disclosure
This analysis was funded by Pfizer Inc. Jeffery Robbins and Barrett W Jeffers are employees of Pfizer Inc. Kazuomi Kario reports no specific funding in relation to this research and has no conflicts of interest to disclose on this paper. Editorial support was provided by Helen Jones, PhD, and Michelle Jenvey, PhD, of Engage Scientific and funded by Pfizer Inc.

References


